$IMUX
Immunic Inc Stock $imux

$imux Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000128077620000015 Filed on May 08, 2020

Income Statement

Concept	2020 Q2	2020 Q1	2019 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.240M	$2.580M	$1.310M
YoY Change	-75.06%	96.95%	-69.82%
% of Gross Profit
Research & Development	$9.987M	$6.434M	$3.355M
YoY Change	65.65%	91.77%	-66.97%
% of Gross Profit
Depreciation & Amortization	$6.000K	$14.00K	$5.000K
YoY Change	-75.0%	180.0%	-97.77%
% of Gross Profit
Operating Expenses	$12.22M	$9.014M	$4.662M
YoY Change	-18.56%	93.35%	103.76%
Operating Profit	-$12.22M	-$9.014M	-$4.662M
YoY Change	-18.56%	93.35%	-67.83%
Interest Expense	$0.00	$20.00K	$0.00
YoY Change	-100.0%		-100.0%
% of Operating Profit
Other Income/Expense, Net	$764.0K	$527.0K	$349.0K
YoY Change	160.75%	51.0%	235.58%
Pretax Income	-$11.46M	-$8.490M	-$4.310M
YoY Change	-22.09%	96.98%	-70.05%
Income Tax
% Of Pretax Income
Net Earnings	-$11.46M	-$8.487M	-$4.313M
YoY Change	-22.13%	96.78%	90.59%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.90	-$0.79
Diluted Earnings Per Share	-$0.90	-$0.79	-$576.2K
COMMON SHARES
Basic Shares Outstanding	12.79M shares	10.74M shares	42.37M shares
Diluted Shares Outstanding			43.71M shares

Balance Sheet

Concept	2020 Q2	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$48.60M	$18.60M	$9.600M
YoY Change	34.63%	93.75%	-77.98%
Cash & Equivalents	$48.60M	$18.60M	$7.593M
Short-Term Investments
Other Short-Term Assets	$655.0K	$670.0K	$400.0K
YoY Change	-73.8%	67.5%	-66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$53.02M	$23.60M	$9.988M
YoY Change	34.26%	136.27%	-77.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$121.0K	$77.00K	$482.0K
YoY Change	181.4%	-84.02%	-76.74%
Goodwill	$32.97M	$32.97M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$42.00K	$42.00K	$12.00K
YoY Change		250.0%	-88.12%
Total Long-Term Assets	$34.13M	$33.69M	$494.0K
YoY Change	3.17%	6720.45%	-77.27%
TOTAL ASSETS
Total Short-Term Assets	$53.02M	$23.60M	$9.988M
Total Long-Term Assets	$34.13M	$33.69M	$494.0K
Total Assets	$87.15M	$57.29M	$10.48M
YoY Change	20.09%	446.58%	-77.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.728M	$1.432M	$184.0K
YoY Change	18.19%	678.26%	-79.4%
Accrued Expenses	$5.450M	$3.963M	$1.215M
YoY Change	243.63%	226.17%	-86.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.674M	$6.333M	$1.433M
YoY Change	145.8%	341.94%	-85.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$800.0K	$500.0K	$0.00
YoY Change	1851.22%
Total Long-Term Liabilities	$793.0K	$471.0K	$0.00
YoY Change	1834.15%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.674M	$6.333M	$1.433M
Total Long-Term Liabilities	$793.0K	$471.0K	$0.00
Total Liabilities	$8.467M	$6.804M	$1.433M
YoY Change	167.69%	374.81%	-85.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.90M	-$68.40M	-$346.9M
YoY Change	81.57%	-80.28%	11.78%
Common Stock	$1.000K	$1.000K	$4.000K
YoY Change	-99.93%	-75.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$78.69M	$50.49M	-$9.770M
YoY Change
Total Liabilities & Shareholders Equity	$87.15M	$57.29M	$10.48M
YoY Change	20.09%	446.58%	-77.7%

Cashflow Statement

Concept	2020 Q2	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$11.46M	-$8.487M	-$4.313M
YoY Change	-22.13%	96.78%	90.59%
Depreciation, Depletion And Amortization	$6.000K	$14.00K	$5.000K
YoY Change	-75.0%	180.0%	-97.77%
Cash From Operating Activities	-$9.230M	-$11.03M	-$5.317M
YoY Change	-15.94%	107.43%	-59.33%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	$4.000K	$7.000K
YoY Change	500.0%	-42.86%	-95.33%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$60.00K	-$4.000K	-$7.000K
YoY Change	-100.64%	-42.86%	-95.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	39.21M	$568.0K	$20.53M
YoY Change	315.36%	-97.23%	-68536.67%
NET CHANGE
Cash From Operating Activities	-9.230M	-$11.03M	-$5.317M
Cash From Investing Activities	-60.00K	-$4.000K	-$7.000K
Cash From Financing Activities	39.21M	$568.0K	$20.53M
Net Change In Cash	29.92M	-$10.79M	$14.95M
YoY Change	284.08%	-172.2%	-212.77%
FREE CASH FLOW
Cash From Operating Activities	-$9.230M	-$11.03M	-$5.317M
Capital Expenditures	-$60.00K	$4.000K	$7.000K
Free Cash Flow	-$9.170M	-$11.03M	-$5.324M
YoY Change	-16.41%	107.23%	-59.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001280776
CY2019Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.025
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36201
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Immunic, Inc.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	56-2358443
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Avenue of the Americas
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2020Q1	dei	City Area Code CityAreaCode	332
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	255-9818
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2020Q1	dei	Trading Symbol TradingSymbol	IMUX
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12793340	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18578000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29369000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5021000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2861000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	23599000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	32230000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	77000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	32970000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	32970000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	604000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	633000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000	USD
CY2020Q1	us-gaap	Assets Assets	57292000	USD
CY2019Q4	us-gaap	Assets Assets	65955000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1432000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2423000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3963000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3298000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	938000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1351000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6333000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7072000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	471000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	520000	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	471000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	520000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	6804000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	6804000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	7592000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	7592000	USD
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10823551	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10823551	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10744806	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10744806	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	120567000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119646000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1682000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1373000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68398000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59911000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	50488000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	58363000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57292000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65955000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6434000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3355000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2580000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1307000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	9014000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4662000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9014000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4662000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	503000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	349000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	527000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	349000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-8487000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4313000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.09
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10749460	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	846953	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-8487000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4313000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-309000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-247000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8796000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4560000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	58363000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-8487000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	353000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-309000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	37000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	50488000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-25741000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4313000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4313000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-247000	USD
CY2019Q1	vtl	Stock Subscription Not Yet Issued StockSubscriptionNotYetIssued	20531000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-9770000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-8487000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	353000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2172000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	252000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-973000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-880000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	704000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	158000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-468000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-35000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11029000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5317000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	568000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	20531000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	568000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20531000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-326000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-260000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10791000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14947000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29369000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13072000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18578000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28019000	USD
CY2020Q1	vtl	Property Plant And Equipment Included In Accounts Payable PropertyPlantAndEquipmentIncludedInAccountsPayable	7000	USD
CY2019Q1	vtl	Property Plant And Equipment Included In Accounts Payable PropertyPlantAndEquipmentIncludedInAccountsPayable	0	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18578000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7593000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	20426000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18578000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28019000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68400000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59900000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18600000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to the application of the acquisition method of accounting related to the Transaction, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.
CY2020Q1	us-gaap	Depreciation Depreciation	14000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	5000	USD
CY2019Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020Q1	vtl	Lessee Operating Leases Number Of Existing Leases LesseeOperatingLeasesNumberOfExistingLeases	4	lease
CY2020Q1	vtl	Lessee Operating Leases Number Of Existing Leases LesseeOperatingLeasesNumberOfExistingLeases	4	lease
CY2019	vtl	Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed Non Cash Charges BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedNonCashCharges	7500000	USD
CY2020Q1	vtl	Prepaid Clinical And Related Costs Current PrepaidClinicalAndRelatedCostsCurrent	3710000	USD
CY2019Q4	vtl	Prepaid Clinical And Related Costs Current PrepaidClinicalAndRelatedCostsCurrent	1307000	USD
CY2020Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	176000	USD
CY2019Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	408000	USD
CY2020Q1	vtl	Research And Development Tax Incentive Current ResearchAndDevelopmentTaxIncentiveCurrent	465000	USD
CY2019Q4	vtl	Research And Development Tax Incentive Current ResearchAndDevelopmentTaxIncentiveCurrent	350000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	670000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	796000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5021000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2861000	USD
CY2020Q1	vtl	Clinical Costs Payable Current ClinicalCostsPayableCurrent	1078000	USD
CY2019Q4	vtl	Clinical Costs Payable Current ClinicalCostsPayableCurrent	1981000	USD
CY2020Q1	vtl	Legal And Audit Costs Payable Current LegalAndAuditCostsPayableCurrent	198000	USD
CY2019Q4	vtl	Legal And Audit Costs Payable Current LegalAndAuditCostsPayableCurrent	226000	USD
CY2020Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	156000	USD
CY2019Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	216000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1432000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2423000	USD
CY2020Q1	vtl	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	3384000	USD
CY2019Q4	vtl	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	2863000	USD
CY2020Q1	vtl	Accrued Legal And Audit Costs Current AccruedLegalAndAuditCostsCurrent	83000	USD
CY2019Q4	vtl	Accrued Legal And Audit Costs Current AccruedLegalAndAuditCostsCurrent	211000	USD
CY2020Q1	vtl	Accrued Compensation Current AccruedCompensationCurrent	284000	USD
CY2019Q4	vtl	Accrued Compensation Current AccruedCompensationCurrent	0	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	212000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	224000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3963000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3298000	USD
CY2020Q1	us-gaap	Other Deferred Credits Current OtherDeferredCreditsCurrent	663000	USD
CY2019Q4	us-gaap	Other Deferred Credits Current OtherDeferredCreditsCurrent	1008000	USD
CY2020Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	275000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	343000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	938000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1351000	USD
CY2020Q1	vtl	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	23000	USD
CY2020Q1	vtl	Operating Lease Incremental Borrowing Rate OperatingLeaseIncrementalBorrowingRate	0.06
CY2020Q1	vtl	Operating And Variable Leases Cost OperatingAndVariableLeasesCost	79000	USD
CY2019Q1	vtl	Operating And Variable Leases Cost OperatingAndVariableLeasesCost	12000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	182000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	75000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	751000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	81000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	270000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	224000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	670000	USD
CY2020Q1	us-gaap	Contractual Obligation ContractualObligation	1700000	USD
CY2016Q2	vtl	Asset Purchase Agreement Royalties As Percent Of Aggregated Net Sales AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales	0.044
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120070	shares
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	1500000	USD
CY2018Q2	vtl	Maximum Aggregate Offering Priceof Securities Under Shelf Registration MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration	200000000.0	USD
CY2018Q2	vtl	Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders	2500000	shares
CY2018Q2	vtl	Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement	60000000.0	USD
CY2019Q3	vtl	Maximum Aggregate Offering Priceof Securities Under Shelf Registration MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration	40000000.0	USD
CY2020Q1	vtl	Shelf Registration Agreement Commission Percent Of Gross Proceeds On Sale Of Common Stock ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock	0.030
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2020Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	156920	shares
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.00
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.00
CY2019Q1	us-gaap	Restricted Cash RestrictedCash	18200000	EUR
CY2019Q1	us-gaap	Restricted Cash RestrictedCash	20500000	USD
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1603964	shares
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2900000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M28D

Files In Submission

Name	View Source	Status
0001280776-20-000015-index-headers.html	Edgar Link	pending
0001280776-20-000015-index.html	Edgar Link	pending
0001280776-20-000015.txt	Edgar Link	pending
0001280776-20-000015-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
imux-033120xexhibit311.htm	Edgar Link	pending
imux-033120xexhibit312.htm	Edgar Link	pending
imux-033120xexhibit321.htm	Edgar Link	pending
imux-033120xexhibit322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtl-20200331.htm	Edgar Link	pending
vtl-20200331.xsd	Edgar Link	pending
vtl-20200331_cal.xml	Edgar Link	unprocessable
vtl-20200331_def.xml	Edgar Link	unprocessable
vtl-20200331_g1.jpg	Edgar Link	pending
vtl-20200331_htm.xml	Edgar Link	completed
vtl-20200331_lab.xml	Edgar Link	unprocessable
vtl-20200331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUX
Immunic Inc Stock $imux

2020 Q2 Form 10-Q Financial Statement

#000128077620000015 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUX Immunic Inc Stock $imux

2020 Q2 Form 10-Q Financial Statement

#000128077620000015 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUX
Immunic Inc Stock $imux